Publicaciones en colaboración con investigadores/as de Tel Aviv University (6)

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  2. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

    Blood, Vol. 141, Núm. 3, pp. 219-230

2021

  1. Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 1, pp. 46-54.e4

2020

  1. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

    Blood Cancer Journal, Vol. 10, Núm. 11

2018

  1. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

    Nature Medicine, Vol. 24, Núm. 12, pp. 1867-1876

2015

  1. Elotuzumab therapy for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631